Moesin Expression in Clear Cell Renal Cell Carcinoma

Expression and Distribution of Membrane-Organizing Extension Spike Protein (Moesin/ MSN) is Associated With Epithelial-Mesenchymal Transition in Clear Cell Renal Cell Carcinoma.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06055660

Enrollment

Registered

2023-09-28

Start date

2017-01-01

Completion date

2021-12-31

Last updated

2023-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Cell Carcinoma

Keywords

Renal Cell Carcinoma, Moesin, Epithelial-Mesenchymal Transition

Brief summary

Renal cell carcinoma (RCC) is the most frequently occurring primary renal neoplasm. There are several histological variants of RCC that are associated with variable prognostic outcomes. Epithelial-mesenchymal transition (EMT) is a phenomenon in which the epithelial cells acquire some mesenchymal criteria as enhanced invasive potential. There are several cell surface molecules that are implicated in EMT. Moesin is one of these molecules that is involved in EMT, which is associated with enhanced invasive potential and poor prognosis. Targeting Moesin by novel therapeutic agents may prevent EMT and improve prognosis of patients with RCC.

Interventions

GENETICImmunohistochemical detection of Moesin in Clear cell Renal Cell Carcinoma

Formalin-fixed paraffin-embedded renal cell carcinoma tissue blocks will be sectioned and immunohistochemically stained by anti moesin antibody.

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Inclusion criteria

1. All cases of ccRCC. 2. Tissue blocks with material adequate for immunohistochemical evaluation. 3. All cases with accessible clinical data.

Exclusion criteria

1. Cases of renal neoplasms other than ccRCC. 2. Patients who received preoperative chemotherapy or radiotherapy. 3. Patients with ccRCC who were diagnosed by tru-cut biopsies only and didn't undergo radical operations. 4. Cases with insufficient/destructed material. 5. Patients with inadequate clinical data.

Design outcomes

Primary

Measure	Time frame	Description
Detection of Moesin in renal cell carcinoma	6 months	different levels of moesin expression will be correlated with some tumor characteristics as patients' ages, sexes, tumor site, tumor grades, stages and nodal statuses.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026